News and Events

News

All categories

Earnings

Press Release

All years

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Announces Listing Transfer to Nasdaq Capital Markets

October 4, 2023

Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

September 27, 2023

Affimed to Present at the Cantor Global Healthcare Conference 2023

September 21, 2023

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK^® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

September 12, 2023

Affimed to Present at the H.C. Wainwright Annual Global Investment Conference

September 7, 2023

Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

August 22, 2023

Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress

August 10, 2023

Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023

August 3, 2023

Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells

July 31, 2023

Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board

June 22, 2023

Events

All

Scientific

Investors

There are no events planned at the moment.

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed Announces Listing Transfer to Nasdaq Capital Markets

Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Affimed to Present at the Cantor Global Healthcare Conference 2023

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK^® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

Affimed to Present at the H.C. Wainwright Annual Global Investment Conference

Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress

Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023

Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells

Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board

Events